Yatsunami J - Search Results

1

Tuberculosis following liver transplantation: report of a case and review of the literature.

Nishizaki T, Yanaga K, Soejima Y, Kishikawa K, Kajiyama K, Uchiyama H, Yatsunami J, Hara N, Sugimachi K. Nishizaki T, et al. Among authors: yatsunami j. Transpl Int. 1996;9(6):589-92. doi: 10.1007/BF00335560. Transpl Int. 1996. PMID: 8914240

2

Empyema following the percutaneous instillation of antifungal agents in patients with aspergillosis.

Nakanishi Y, Wakamatsu K, Nomoto Y, Kawasaki M, Takayama K, Yatsunami J, Tsuruta N, Hashimoto S, Hara N. Nakanishi Y, et al. Among authors: yatsunami j. Intern Med. 1996 Aug;35(8):657-9. doi: 10.2169/internalmedicine.35.657. Intern Med. 1996. PMID: 8894743 Free article.

3

Chronic bronchobronchiolitis obliterans associated with Stevens-Johnson syndrome.

Yatsunami J, Nakanishi Y, Matsuki H, Wakamatsu K, Takayama K, Kawasaki M, Ogino H, Hashimoto S, Hara N. Yatsunami J, et al. Intern Med. 1995 Aug;34(8):772-5. doi: 10.2169/internalmedicine.34.772. Intern Med. 1995. PMID: 8563119 Free article.

4

Bcl-2 expression as a predictor of chemosensitivities and survival in small cell lung cancer.

Takayama K, Ogata K, Nakanishi Y, Yatsunami J, Kawasaki M, Hara N. Takayama K, et al. Among authors: yatsunami j. Cancer J Sci Am. 1996 Jul-Aug;2(4):212-6. Cancer J Sci Am. 1996. PMID: 9166534

5

P53 immunostaining predicts chemosensitivity in non-small cell lung cancer: A preliminary report.

Kawasaki M, Nakanishi Y, Yatsunami J, Takayama K, Ochiai S, Xinhai P, Kuwano K, Hara N. Kawasaki M, et al. Among authors: yatsunami j. Cancer J Sci Am. 1996 Jul-Aug;2(4):217-20. Cancer J Sci Am. 1996. PMID: 9166535

6

Phase II trial of dose intensification with cisplatin and carboplatin plus vindesine in patients with inoperable non-small cell lung cancer.

Nakanishi Y, Takayama K, Kawasaki M, Yatsunami J, Inutsuka S, Wakamatsu K, Tsuruta N, Hara N. Nakanishi Y, et al. Among authors: yatsunami j. Am J Clin Oncol. 1997 Aug;20(4):393-7. doi: 10.1097/00000421-199708000-00015. Am J Clin Oncol. 1997. PMID: 9256897 Clinical Trial.

7

Clarithromycin is a potent inhibitor of tumor-induced angiogenesis.

Yatsunami J, Turuta N, Wakamatsu K, Hara N, Hayashi S. Yatsunami J, et al. Res Exp Med (Berl). 1997;197(4):189-97. doi: 10.1007/s004330050068. Res Exp Med (Berl). 1997. PMID: 9440137

8

The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer.

Kawasaki M, Nakanishi Y, Kuwano K, Yatsunami J, Takayama K, Hara N. Kawasaki M, et al. Among authors: yatsunami j. Clin Cancer Res. 1997 Jul;3(7):1195-200. Clin Cancer Res. 1997. PMID: 9815799

9

Inhibition of tumor angiogenesis by roxithromycin, a 14-membered ring macrolide antibiotic.

Yatsunami J, Tsuruta N, Hara N, Hayashi S. Yatsunami J, et al. Cancer Lett. 1998 Sep 25;131(2):137-43. doi: 10.1016/s0304-3835(98)00110-4. Cancer Lett. 1998. PMID: 9851245

10

Glutathione derivatives enhance adriamycin cytotoxicity in a human lung adenocarcinoma cell line.

Nakanishi Y, Matsuki H, Takayama K, Yatsunami J, Kawasaki M, Abe M, Hara N. Nakanishi Y, et al. Among authors: yatsunami j. Anticancer Res. 1997 May-Jun;17(3C):2129-34. Anticancer Res. 1997. PMID: 9216676

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

44 results

Search Page

Filters